January 11, 2018 09:31 AM EST

Charles River buys KWS BioTest for $20M, gaining immunology discovery capacity and a UK footprint

Amber Tong

In a move to expand its discovery enterprise, Charles River Laboratories $CRL has acquired KWS BioTest for £15 million (roughly $20 million) up front. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Charles River buys KWS BioTest for $20M, gaining immunology discovery capacity and a UK footprint

Amber Tong

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Gilead buys experimental HIV vaccines from a small Barcelona biotech

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Charles Riv­er buys KWS BioTest for $20M, gain­ing im­munol­o­gy dis­cov­ery ca­pac­i­ty and a UK foot­print

Amber Tong

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Charles River buys KWS BioTest for $20M, gaining immunology discovery capacity and a UK footprint

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Gilead buys experimental HIV vaccines from a small Barcelona biotech

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA